Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2024-06-03 Board/Management Inform…
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
ALK launches new growth strategy and 2028 financial ambitions
Board/Management Information Classification · 95% confidence The document is a corporate announcement regarding a new growth strategy ('Allergy+') and financial ambitions for 2028. It details strategic pillars, capital allocation, and future outlook. While it contains significant strategic information, it is structured as a formal regulatory announcement (press release) issued via a wire service (GlobeNewswire), and it explicitly includes a link to an attached file ('Vedhæftet fil') containing the full strategy presentation. According to the 'Menu vs Meal' rule, since this is an announcement of a report/strategy rather than the full investor presentation deck itself, it is classified as a Report Publication Announcement.
2024-06-03 Danish
ALK launches new growth strategy and 2028 financial ambitions
Regulatory Filings Classification · 95% confidence The document is a company release (No 12/2024) from ALK announcing a new corporate strategy ('Allergy+') and 2028 financial ambitions. It details strategic pillars, growth targets, and capital allocation plans. While it discusses financial goals, it is an announcement of a strategic plan rather than a formal quarterly or annual financial report. It also mentions an upcoming Capital Markets Day. Given the nature of the document as a strategic update and corporate announcement, it fits best under 'Regulatory Filings' (RNS) as a general corporate announcement that does not fall into the more specific categories like 10-K, IR, or IP (as it is a release, not the presentation deck itself).
2024-06-03 English
Earnings Release 2024
Earnings Release Classification · 95% confidence The document is a short announcement titled "ALK opjusterer sine salgsforventninger for helåret" (ALK adjusts its sales expectations for the full year). It details revised guidance for 2024 revenue and EBIT margin, and crucially, announces the acceleration of the release date for the Q1 interim report from May 3rd to May 2nd, 2024. Since the document is short (1872 chars) and its primary function is to communicate updated guidance and the timing of another report's release, it fits best as an Earnings Release (ER) which typically covers key financial highlights and guidance changes, or potentially a Regulatory Filing (RNS) if it were purely a mandatory disclosure without financial context. Given the explicit mention of updated sales expectations and EBIT margin forecasts, 'ER' (Earnings Release) is the most appropriate classification, as it precedes the full Interim Report (IR) which is being released today. It is not an announcement of a report's publication (RPA) because it contains substantive financial guidance updates itself. Q1 2024
2024-05-02 Danish
Earnings Release 2024
Earnings Release Classification · 100% confidence The document is very short (1613 characters) and announces an update to the full-year revenue outlook and EBIT margin expectations. Crucially, it states: "ALK has decided to advance the release of its first quarter results. The Q1 report, originally due for 3 May 2024, will be published today, 2 May 2024." This structure—providing key financial highlights (outlook update) and announcing the immediate release of a more detailed report (Q1 report)—is characteristic of an Earnings Release (ER). It is not the full report itself (which would be an IR), nor is it just an announcement about the publication timing (RPA), as it contains substantive financial updates (outlook change). FY 2024
2024-05-02 English
ALK upgrades its full-year revenue outlook
Earnings Release Classification · 95% confidence The document is a short announcement (under 5,000 characters) from ALK-Abelló regarding an upward adjustment of their full-year sales guidance. It also mentions the early release of a quarterly report and provides a link to an attached file. According to the 'Menu vs Meal' rule, since this is a short announcement of financial guidance and refers to an attached report, it is classified as a Report Publication Announcement (RPA). FY 2024
2024-05-02 Danish
ALK upgrades its full-year revenue outlook
Earnings Release Classification · 95% confidence The document is a short announcement (under 2,000 characters) regarding an update to the company's full-year financial outlook and a change in the publication date for the Q1 report. It explicitly mentions an 'Attachment' containing the actual report. According to the 'Menu vs Meal' rule, since this is a short announcement about a report being published or updated, it is classified as a Report Publication Announcement (RPA). Q1 2024
2024-05-02 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.